Trial Profile

A Phase III Randomized, Modified Double-blind, Active-controlled, Multi-center Study to Describe the Immunogenicity and Safety of the Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

31 Oct 2022 Status changed from active, no longer recruiting to completed.
01 Jul 2022 Planned End Date changed from 6 Sep 2022 to 14 Sep 2022.
01 Jul 2022 Planned primary completion date changed from 6 Sep 2022 to 14 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com